CA3173611A1 - Treating pulmonary inflammatory disease associated with covid-19 by administering resiniferatoxin - Google Patents

Treating pulmonary inflammatory disease associated with covid-19 by administering resiniferatoxin Download PDF

Info

Publication number
CA3173611A1
CA3173611A1 CA3173611A CA3173611A CA3173611A1 CA 3173611 A1 CA3173611 A1 CA 3173611A1 CA 3173611 A CA3173611 A CA 3173611A CA 3173611 A CA3173611 A CA 3173611A CA 3173611 A1 CA3173611 A1 CA 3173611A1
Authority
CA
Canada
Prior art keywords
composition
pulmonary
rtx
inflammatory disease
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3173611A
Other languages
English (en)
French (fr)
Inventor
Alexis Nahama
Henry Hongjun Ji
Irving H. ZUCKER
Hanjun Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sorrento Therapeutics Inc
University of Nebraska System
Original Assignee
Sorrento Therapeutics Inc
University of Nebraska System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorrento Therapeutics Inc, University of Nebraska System filed Critical Sorrento Therapeutics Inc
Publication of CA3173611A1 publication Critical patent/CA3173611A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA3173611A 2020-03-30 2021-03-12 Treating pulmonary inflammatory disease associated with covid-19 by administering resiniferatoxin Pending CA3173611A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063002165P 2020-03-30 2020-03-30
US63/002,165 2020-03-30
US202063122858P 2020-12-08 2020-12-08
US63/122,858 2020-12-08
PCT/US2021/022089 WO2021202084A1 (en) 2020-03-30 2021-03-12 Treating pulmonary inflammatory disease associated with covid-19 by administering resiniferatoxin

Publications (1)

Publication Number Publication Date
CA3173611A1 true CA3173611A1 (en) 2021-10-07

Family

ID=75340289

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3173611A Pending CA3173611A1 (en) 2020-03-30 2021-03-12 Treating pulmonary inflammatory disease associated with covid-19 by administering resiniferatoxin

Country Status (8)

Country Link
US (1) US20230143545A1 (https=)
EP (1) EP4125871A1 (https=)
JP (2) JP2023519853A (https=)
KR (1) KR20220161423A (https=)
CN (1) CN115666551A (https=)
AU (1) AU2021248861A1 (https=)
CA (1) CA3173611A1 (https=)
WO (1) WO2021202084A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL300072A (en) * 2020-08-11 2023-03-01 Sorrento Therapeutics Inc Treatment of pneumonia by nerve ablation
WO2025153517A1 (en) 2024-01-15 2025-07-24 Grünenthal GmbH Treating knee joint pain by injecting resiniferatoxin at ultra low doses

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2187193B (en) 1986-02-27 1989-11-08 Gerald Scott Controllably and swiftly degradable polymer compositions and films and other products made therefrom
US5021450A (en) 1989-05-30 1991-06-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services New class of compounds having a variable spectrum of activities for capsaicin-like responses, compositions and uses thereof
US5232684A (en) 1990-06-29 1993-08-03 The United States Of America As Represented By The Department Of Health And Human Services Labelled resiniferatoxin, compositions thereof, and methods for using the same
GB9826359D0 (en) * 1998-12-01 1999-01-27 Glaxo Group Ltd Novel receptors
CA2880855A1 (en) 2012-08-03 2014-02-06 Mestex Ag Resiniferatoxin solution
EP3131541A4 (en) * 2014-04-14 2018-02-14 Flex Pharma, Inc. Ion channel activators and methods of use
US20200129472A1 (en) * 2017-02-09 2020-04-30 Board Of Regents Of The University Of Nebraska Compositions and methods for the treatment of peripheral artery disease
MX2020002692A (es) * 2017-09-11 2020-10-14 Sorrento Therapeutics Inc Formulacion de resiniferatoxina.

Also Published As

Publication number Publication date
EP4125871A1 (en) 2023-02-08
CN115666551A (zh) 2023-01-31
JP2023519853A (ja) 2023-05-15
US20230143545A1 (en) 2023-05-11
AU2021248861A1 (en) 2022-10-13
WO2021202084A1 (en) 2021-10-07
JP2026042884A (ja) 2026-03-11
KR20220161423A (ko) 2022-12-06

Similar Documents

Publication Publication Date Title
DE69525971T3 (de) Verwendung eines pm-1 antikörpers oder eines mh 166 antikörpers zur verstärkung des anti-tumor-effektes von cisplatin oder carboplatin
FI106433B (fi) Menetelmä farmaseuttisen formulaation valmistamiseksi, joka soveltuu granulosyyttipesäkkeitä stimuloivan tekijän antamiseen keuhkojen kautta
CA3173611A1 (en) Treating pulmonary inflammatory disease associated with covid-19 by administering resiniferatoxin
JP2022187002A (ja) 抗腫瘍ｔ細胞応答増強剤
US6747036B2 (en) Methods of treating leukemia
US20090220500A1 (en) Agents for treating cardiopathy
JP2022528324A5 (https=)
EP3569235A1 (en) Use of aerosolized levofloxacin for treating cystic fibrosis
RU2008135580A (ru) Альфа-1-антитрипсин для лечения эпизодов воспаления болезней легких
JP2003531867A (ja) 抗体および抗炎症薬を用いた呼吸器疾患の組合せ治療法
JP2023519853A5 (https=)
CA3188689A1 (en) Treating pulmonary inflammatory disease by neural ablation
Terzano et al. Early protective effects of tiotropium bromide in patients with airways hyperresponsiveness
US20210121528A1 (en) Compositions for treating lung infections by airway administration
RU2020118032A (ru) Способы лечения болезни фарбера
Shaw et al. Childhood acute myeloid leukemia: outcome in a single center using chemotherapy and consolidation with busulfan/cyclophosphamide for bone marrow transplantation.
EP2877199A1 (en) Granulocyte-macrophage colony-stimulating factor for the treatment of bronchial asthma
US5780012A (en) Method for reducing lung afflictions by inhalation of cytokine solutions
CA2928736A1 (en) Inhaled aerosolized immuno-chemotherapy for the treatment of mdr tb
DE19739693A1 (de) Pharmazeutische Präparate zur Behandlung der Multiplen Sklerose
EP4188433A2 (en) Targeted delivery of therapeutic agents
US12115182B2 (en) Adenosine A2A agonists for the treatment of cytokine storm syndrome
EP2944310B1 (en) MIF inhibitors for the acute or chronic treatment of pulmonary hypertension
IL275328B1 (en) Methods for inducing immune tolerance and reducing antibody response against drugs
Park et al. Plasma Lidocaine Concentration and Hemodynamic Effect after 10% Lidocaine Spray on Laryngopharyngeal and Intratracheal Site during the Endotracheal Intubation.

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220927

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241001

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE

Effective date: 20241210

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241210

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R125 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMMON REPRESENTATIVE APPOINTED

Effective date: 20250311

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250311

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250827

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250829

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250829

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251224

C11 Application revival requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-C10-C11-C106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REINSTATEMENT REQUEST RECEIVED

Effective date: 20260130

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260130

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260423